SCHEMBL24024486

SCHEMBL24024486

NC(=O)c1cn([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)cn1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATIC P31939 3/20 0.62
FBP1 P09467 3/20 0.62
LDHA P00338 2/20 0.53
TAS1R3 Q7RTX0 3/20 0.52
TAS1R1 Q7RTX1 3/20 0.52
DNPH1 O43598 1/20 0.52
PRKAB2 O43741 1/20 0.52
TRPM2 O94759 1/20 0.52
ADRB2 P07550 1/20 0.52
SRC P12931 1/20 0.52
ADORA1 P30542 1/20 0.52
P2RY2 P41231 1/20 0.52
P2RY1 P47900 1/20 0.52
PRKAG1 P54619 1/20 0.52
PRKAA2 P54646 1/20 0.52
PDE4D Q08499 1/20 0.52
KCNH2 Q12809 1/20 0.52
PRKAA1 Q13131 1/20 0.52
PDE3A Q14432 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29687021 1.00 ATIC (0.62) ATICFBP1LDHATAS1R3TAS1R1
SCHEMBL4358224 0.90 ATIC (0.55) ATICFBP1LDHATAS1R3TAS1R1
SCHEMBL2510742 0.89 FBP1 (0.54) ATICFBP1LDHATAS1R3TAS1R1
SCHEMBL17270349 0.82 ATIC (0.41) ATICFBP1ADORA1SMN1; SMN2
SCHEMBL8722885 0.82 LMNA (0.57) ADORA1SMN1; SMN2
SCHEMBL12669988 0.82 LMNA (0.57) ADORA1SMN1; SMN2
SCHEMBL7213155 0.82 LMNA (0.57) ADORA1SMN1; SMN2
SCHEMBL6385747 0.82 LMNA (0.57) ADORA1SMN1; SMN2
SCHEMBL2481555 0.82 LMNA (0.57) ADORA1SMN1; SMN2
SCHEMBL12676402 0.82 LMNA (0.57) ADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353660-A1 Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs OCTAGON THERAPEUTICS INC. (US) 2021-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353660-A1 Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs IMPDH1, IMPDH2, PNP ATIC 86/4885FBP1 527/4885LDHA 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.